SCHEMBL4816568

SCHEMBL4816568

[CH2]/C=C/c1cc2ccccc2c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.49
TRPM4 Q8TD43 1/20 0.43
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 3/20 0.43
HIF1A Q16665 2/20 0.43
CYP1B1 Q16678 1/20 0.43
HPRT1 P00492 3/20 0.41
TSHR P16473 2/20 0.39
CYP2A6 P11509 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GPR84 Q9NQS5 1/20 0.37
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
RAD52 P43351 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
CYP1A2 P05177 2/20 0.35
ERBB2 P04626 1/20 0.35
FYN P06241 1/20 0.35
MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11798289 0.79 MAOB (0.49) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL11798296 0.79 MAOB (0.49) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL31180384 0.78 TRPM4 (0.46) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL1813416 0.78 TRPM4 (0.46) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL2845190 0.78 ALDH1A1 (0.50) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL554004 0.75 MAOB (0.45) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL554003 0.75 MAOB (0.45) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL29961731 0.75 MAOB (0.45) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL1972157 0.74 TRPM4 (0.46) MAOBTRPM4ALDH1A1HSD17B10HIF1A
SCHEMBL3100920 0.74 RXRA (0.53) ALDH1A1CYP1B1MAPTCYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US claimed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US claimed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP claimed
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US disclosed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US disclosed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 MAOB 1167/4885TRPM4 2810/4885ALDH1A1 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.